ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with ...

In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings ...

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity ...

Zanidatamab was previously approved by the U.S. Food and Drug Administration (FDA) in November 2024 and had a positive ...

When placed under a powerful laser field (i.e., under strong-field ionization), electrons can temporarily cross the so-called ...

The question of how life could have emerged is one of the most long-standing mysteries in science. In a new study, the ...

MRD positivity or reappearance was prognostic for earlier clinical relapse. This study leverages a large phase III trial to demonstrate the association of MRD status with outcomes in patients with FL.

Scientists have documented the way a single gene in the bacterium that causes bubonic plague, Yersinia pestis, allowed it to ...

A change to a single gene in the bacterium Yersinia pestis has enabled one of the world’s most notorious pathogens to survive ...

Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

We show here that in a transgenic mouse model, inflammatory mediators induced expression of FcαRI on Kupffer cells, which enabled efficient phagocytosis in vivo of bacteria coated with serum IgA.